Stock AZN ASTRAZENECA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings AstraZeneca PLC Nasdaq

Equities

AZN

US0463531089

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
75.17 USD +0.19% Intraday chart for AstraZeneca PLC +9.66% +11.61%
04-26 ASTRAZENECA : DZ Bank sticks Neutral ZD
04-26 ASTRAZENECA : UBS keeps a Sell rating ZD

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ASTRAZENECA PLC Stock AstraZeneca PLC
+11.61% 231B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
PFIZER, INC. Stock Pfizer, Inc.
-11.77% 144B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. AZN Stock
  5. Ratings AstraZeneca PLC